

In the Claims

Please amend claims 4 and 30 as set forth below.

1. (previously presented) A method for administering a therapeutic medium to a posterior segment of an eye, the method comprising the step of: instilling the therapeutic medium sub-retinally; wherein said instilling comprises injecting a solution including the therapeutic medium in the sub-retinal space.

2. (original) The administering method of claim 1, wherein said step of instilling includes localizing the action of the therapeutic medium at the choroid and the retina and minimizing action at other tissues of the eye.

3. (original) The administering method of claim 1, wherein the therapeutic medium being administered is one of a drug, medicament, antiproliferative, neuroprotective, steroidal anti-inflammatory, non-steroidal anti-inflammatory, growth factor, neurotropic factor, antiangiogenic, thrombolytic or a gene.

4. (currently amended) The administering method of claim 3, wherein the steroidal anti-[inflammatory] inflammatory is selected from the group consisting of triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.

5. (original) The administering method of claim 1, wherein a disease state to be treated is selected from the group consisting of ocular neovascularization, ocular inflammation and retinal degeneration.

6. (original) The administering method of claim 1, wherein said step of instilling includes forming a depot of a drug between the choroid and the retina.

7. (canceled)

8. (previously presented) The administering method of claim 1, wherein said step of instilling includes injecting a solution including the therapeutic medium between the choroid and the retina.

9-10. (canceled)

11. (original) The administering method of claim 1, wherein said step of instilling includes: creating a localized retinal detachment to define a sub-retinal space; and disposing the therapeutic medium in the sub-retinal space formed by the localized retinal detachment.

12-19. (canceled).

20. (previously presented) A method for treating an eye, comprising the step of: administering a therapeutic medium to a posterior segment of an eye sub-retinally; wherein said administering comprises (a) forming a sub-retinal space; and (b) injecting a solution including the therapeutic medium in the sub-retinal space.

21-26. (canceled)

27. (previously presented) The eye treatment method of claim 20, further comprising the step of controllably releasing over time the sub-retinally administered therapeutic medium.

28-29. (canceled)

30. (currently amended) The administering method of claim 20 [29], wherein said step of [instilling] injecting includes localizing the action of the steroid at the choroid and the retina and minimizing action at other tissues of the eye.

31-57. (canceled)

58. (previously presented) A method for administering a therapeutic medium to a posterior segment of an eye, the method comprising the step of:

implanting a sustained release delivery device in a sub-retinal space; wherein said sustained release delivery device comprises:

- (a) a core comprising a biocompatible matrix and the therapeutic medium; and
- (b) a jacket surrounding the core comprising a biocompatible membrane comprising a polymer selected from polyacrylates, polyvinylidenes, polyvinyl chloride copolymers, polyurethanes, polystyrenes, polyamides, cellulose acetates, cellulose nitrates, polysulfones, polyphosphazenes, polyacrylonitriles, poly(acrylonitrile/covinyl chloride), derivatives, copolymers, and mixtures thereof.

59. (previously presented) The administering method of claim 58, wherein said step of implanting includes localizing the action of the therapeutic medium at the choroid and the retina and minimizing action at other tissues of the eye.

60. (previously presented) The administering method of claim 58, wherein the therapeutic medium being administered is one of a drug, medicament, antiproliferative, neuroprotective, steroidal anti-inflammatory, non-steroidal anti-inflammatory, growth factor, neurotropic factor, antiangiogenic, thrombolytic or a gene.

61. (previously presented) The administering method of claim 60, wherein the steroidal anti-inflammatory is selected from the group consisting of triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.

Applicant: de Juan, et al
Serial No.: 10/507,461
Filed: September 10, 2004

Examiner: Carter, Kendra D..
Group Art Unit: 1617
Docket No.: SRM0045/US

Title: METHOD FOR SUBRETINAL ADMINISTRATION OF THERAPEUTICS INCLUDING STEROIDS;
METHODS FOR LOCALIZING PHARMACODYNAMIC ACTION AT THE CHOROID AND THE RETINA; AND
RELATED METHODS FOR TREATMENT AND/OR PREVENTION OF RETINAL DISEASES

62. (previously presented) The administering method of claim 58, wherein a disease state to be treated is selected from the group consisting of ocular neovascularization, ocular inflammation and retinal degeneration.

63. (previously presented) The administering method of claim 58, wherein said step of instilling includes: creating a localized retinal detachment to define a sub-retinal space; and implanting the implant in the sub-retinal space formed by the localized retinal detachment.

64. (previously presented) The administering method of claim 58, wherein the sustained release device is configured to provide a sustained sub-retinal release of the therapeutic medium.